Form 4: BioCryst Pharmaceuticals Director Receives Automatic Equity Grants

BioCryst Pharmaceuticals, Inc. Director Vincent Milano was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

Summary

• BioCryst Pharmaceuticals, Inc. Director Vincent Milano received an automatic grant of 12,500 Restricted Stock Units (RSUs) on June 12, 2025.
• These RSUs were granted at a price of $0 and are set to vest on the first anniversary of the grant date, in accordance with the company's Non-Employee Director Compensation Policy.
• Following this RSU grant, Mr. Milano's direct beneficial ownership of common stock stands at 89,760 shares.
• Additionally, Mr. Milano was granted 27,181 automatic stock options on June 12, 2025, with an exercise price of $10.4.
• These stock options will become exercisable on June 12, 2026, and are set to expire on June 12, 2035, also under the Director Compensation Policy.
• His direct beneficial ownership of derivative securities (stock options) following this transaction is 27,181.
• A Power of Attorney dated June 11, 2025, authorizes Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports, including Forms 3, 4, and 5, on behalf of Mr. Milano.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing automatic equity compensation grants to a non-employee director. It contains no information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral sentiment.

Positives

• The automatic equity grants to Director Vincent Milano align his interests with those of the shareholders, as his compensation is tied to the company's stock performance.
• The grants are part of a pre-existing, amended Non-Employee Director Compensation Policy, indicating a structured and transparent approach to director remuneration.

Future Outlook

The document indicates that the 12,500 Restricted Stock Units granted to Director Vincent Milano will vest on the first anniversary of the grant date (June 12, 2026). The 27,181 stock options granted will become exercisable on June 12, 2026, and will expire on June 12, 2035.

Management Comments

• The grants are described as "Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended."
• The stock options are also described as "Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

Industry Context

It is a common and standard practice for publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like BioCryst Pharmaceuticals, to compensate non-employee directors with equity-based awards such as Restricted Stock Units and stock options. This practice aims to align the interests of the directors with those of the shareholders, incentivizing long-term company performance and value creation.

Comparison to Industry Standards

• The compensation structure, involving automatic grants of RSUs and stock options, is a standard practice for non-employee directors across various industries, including the pharmaceutical sector.
• While specific comparable companies or projects are not detailed in this filing, similar equity compensation plans are prevalent at companies like Amgen Inc., Gilead Sciences, Inc., and Vertex Pharmaceuticals Incorporated, where director compensation often includes a mix of cash retainers and equity awards to foster long-term alignment. The vesting schedule (one year for RSUs) and option terms (10-year expiration) are also typical for such grants.

Corporate Governance

Related Party Transactions

• The automatic grants of Restricted Stock Units and stock options to Director Vincent Milano constitute transactions with a related party (a director), conducted under the company's established compensation policy.

Stakeholder Impact

• Shareholders: The grants represent a form of potential dilution as new shares will be issued upon vesting of RSUs and exercise of options, but they also align the director's interests with long-term shareholder value creation.

Next Steps

• Vesting of 12,500 Restricted Stock Units on June 12, 2026.
• Stock options for 27,181 shares becoming exercisable on June 12, 2026.
• Potential exercise of stock options by June 12, 2035.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Director Compensation, Restricted Stock Units, Stock Options, Insider Transaction, Equity Grant, Corporate Governance